Pharma BD Deal Intelligence
A partial win: Lenvima's Keytruda-combo alliance grew into a steady ~$1B/year revenue line for Merck, anchored by real FDA approval in endometrial cancer with confirmed 5-year survival benefit. But the broader "LEAP" expansion into liver, skin, and lung cancers largely failed, with multiple late-stage trials missing survival endpoints and getting discontinued.
Lenvima became a durable ~$1B/year alliance revenue line for Merck, but the ambitious "LEAP" program to extend Keytruda+Lenvima across 6+ tumor types mostly failed — a partial win riding on one real approval (endometrial cancer) amid a long trial-failure streak.
Full analysis, sources & comparables →Evercore ISI's Umer Raffat noted 'Merck has been extremely focused on flawless trial execution with IO-chemo and has added two important small molecule…
Analysts at the time of CLEAR data viewed KEYTRUDA-LENVIMA as the leading IO-TKI combo in RCC on cross-trial comparisons vs Bristol Myers' Opdivo+Cabometyx,…
LEAP-002 missed in 1L HCC, leading Merck and Eisai to scrap that ambition; analysts framed the readout as a setback that ceded ground to Roche's…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Merck and Eisai entered a global strategic oncology collaboration to co-develop and co-commercialize lenvatinib (LENVIMA) as monotherapy and in combination with KEYTRUDA (pembrolizumab). Eisai received $300M upfront, up to $650M in option exercise rights through 2020, $450M in R&D reimbursement, plus up to $385M in clinical/regulatory milestones and up to $3.97B in sales-based milestones (~$5.76B aggregate). Eisai books global sales; gross profits split 50/50.
Lenvima became a durable ~$1B/year alliance revenue line for Merck, but the ambitious "LEAP" program to extend Keytruda+Lenvima across 6+ tumor types mostly failed — a partial win riding on one real approval (endometrial cancer) amid a long trial-failure streak.
Assessment window: 10yr post-close.
82K US cases/yr · $1.5B Global lenvatinib market $1.48B in 2024 (CAGR 8.2% to 2033)
Lenvatinib (LENVIMA) is a multi-receptor tyrosine kinase inhibitor (VEGFR1-3, FGFR1-4, RET, KIT, PDGFR-α) approved across thyroid cancer, renal cell carcinoma (in combination with everolimus or pembrolizumab), hepatocellular carcinoma (1L monotherapy), and endometrial carcinoma (with pembrolizumab). The Merck-Eisai collaboration centered on combining lenvatinib's anti-angiogenic activity with KEYTRUDA's PD-1 blockade to drive synergistic responses across multiple solid tumors with limited durable IO activity as monotherapy.
In advanced RCC at deal time, the standard of care was sunitinib (Pfizer's Sutent) and pazopanib (Votrient); the LENVIMA+KEYTRUDA combination went on to deliver superior PFS/OS vs sunitinib in CLEAR (KEYNOTE-581), supporting a first-line approval in 2021 and competing directly with Bristol Myers' Opdivo+Cabometyx (CheckMate-9ER) and Opdivo+Yervoy combinations (Fierce Pharma, https://www.fiercepharma.com/marketing/data-favor-merck-eisai-s-keytruda-lenvima-as-winner-kidney-cancer-but-window-still-open). In 1L HCC, lenvatinib monotherapy received FDA approval August 2018 based on REFLECT (non-inferior to sorafenib/Nexavar), then was leapfrogged by Roche's atezolizumab+bevacizumab (Tecentriq+Avastin) and AstraZeneca's Imjudo+Imfinzi. In endometrial cancer, KEYTRUDA+LENVIMA established a new standard of care in pMMR advanced disease via KEYNOTE-775 (BioPharma Dive, https://www.biopharmadive.com/news/eisai-merck-lenvima-approval-indication-deal-cancer/530461/). Several Phase 3 readouts disappointed (LEAP-002 HCC, LEAP-006/007 NSCLC, LEAP-010 head & neck, LEAP-012 NSCLC, LEAP-015 GE adenocarcinoma) — a reminder that the combination thesis didn't generalize universally, but the validated indications anchored multi-billion-dollar franchise sales.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Eisai Co., Ltd. (this deal) | 2017 | $5.8B | 57 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2017 deals · Merck & Co. Inc. deals · Nephrology deals